Previsioni

Il prezzo obiettivo medio degli analisti è +25,89€ (+40,33%). La mediana è +22,31€ (+20,92%).

Acquista	24
Mantieni	15
Vendi	0

Notizie Vai al feed delle notizie

Tandem Diabetes relies on pharmacy model, Mobi‑Patch and international direct sales for growth

Tandem Diabetes unveiled a long-term growth plan that includes a pharmacy-based pay-as-you-go model in the US, broader rollout of the tubeless Mobi‑Patch pump in the second half of 2026, and expansion of direct sales activities in selected international markets. The new US model is intended to remove the initial cost barrier for patients and bring up to 80% of US sales through pharmacies; internationally, the company expects higher prices and better follow-on care via direct business. New patient starts stalled in the second quarter, but Tandem expects growth in the second half of the year driven by product dynamics, seasonal demand and additional PBM coverage. At the same time, the company is advancing automation projects, including development toward a fully closed‑loop insulin system and integration of existing CGM technologies. » Altro su de.investing.com
Tandem Diabetes Care beats profit forecasts, shares fall after slight revenue miss

Tandem Diabetes Care reported adjusted EPS of -$0.31 for Q2, beating the analyst estimate of -$0.33, while revenue of $254.6 million missed estimates only slightly. Gross margin rose to 57% and adjusted EBITDA margin reached 3%, marking the fourth consecutive positive quarter. Management reaffirmed the full-year outlook, highlighted record shipments and progress in pharmacy distribution, and expects approval of Mobi Tubeless in the second half of 2026. The stock fell about 4.1% in regular trading and recovered slightly in after-hours trading. » Altro su de.investing.com
Tandem Diabetes Care lags after reimbursement shift clouds near-term revenue

Meridian Small Cap Growth Fund said Tandem Diabetes Care underperformed in Q2 as its transition to a pharmacy-based, pay-as-you-go reimbursement model reduced near-term revenue visibility and second-quarter guidance missed expectations. The fund noted added caution from a new competing patch-pump entrant and that Tandem’s lower-beta profile lagged in a market favoring high-beta names. Meridian remains invested, citing the company’s differentiated pump technology, growing installed base and recurring supply revenue, and views the reimbursement change as a long-term positive. » Altro su finance.yahoo.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2023, Tandem Diabetes Care ha già distribuito 1,14€ di dividendi. L'ultimo pagamento è avvenuto a aprile 2023.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Tandem Diabetes Care ha registrato ricavi pari a 223,05M€ e un utile netto di −18,55M€

(EUR)	giu 2026	YoY
Ricavi	+223,05M	9,23%
Utile lordo	+126,86M	18,81%
Utile netto	−18,55M	58,28%
EBITDA	−8,09M	81,23%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,26Md€
Numero di azioni	68,53M
Massimo/minimo a 52 settimane	+25,44€ - +9,83€
Dividendi	No
Beta	1,54
Rapporto P/E	−23,05
Rapporto PEG	−0,21
Rapporto P/B	+11,23
Rapporto P/S	+1,41

Profilo aziendale

Tandem Diabetes Care, Inc. ist ein Medizintechnikunternehmen, das verschiedene Produkte für Menschen mit insulinabhängigem Diabetes in den Vereinigten Staaten und international entwickelt und vertreibt. Das Flaggschiffprodukt des Unternehmens ist das t:slim X2-Insulinverabreichungssystem, eine Pumpenplattform, die die t:slim X2-Pumpe, eine Einweginsulinpatrone mit 300 Einheiten und ein Infusionsset umfasst. Darüber hinaus bietet das Unternehmen t:slim X2-Insulin mit Basal-IQ- und Control-IQ-Technologie, t:slim X2 mit G5-Integration und Tandem Device Updater, ein Tool, mit dem Benutzer die Software ihrer Pumpe aktualisieren können. Darüber hinaus bietet das Unternehmen t:connect an, eine webbasierte Datenverwaltungsanwendung, die eine visuelle Möglichkeit bietet, Diabetes-Therapiemanagementdaten von der Pumpe, der kontinuierlichen Glukosemessung und den unterstützten Blutzuckermessgeräten für Benutzer, ihre Betreuer und ihre Gesundheitsdienstleister anzuzeigen, sowie Sugarmate, eine mobile Anwendung für Menschen mit Diabetes, die Insulin verwenden. Das Unternehmen hat Entwicklungs- und Vermarktungsvereinbarungen mit Dexcom, Inc. und Abbott Laboratories. Das Unternehmen war früher als Phluid Inc. bekannt und änderte im Januar 2008 seinen Namen in Tandem Diabetes Care, Inc. Tandem Diabetes Care, Inc. wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.

Nome	Tandem Diabetes Care
CEO	John F. Sheridan
Sede centrale	San Diego, ca Stati Uniti
Sito web	tandemdiabetes.com
Settore	Sanità
Industria	Attrezzature e forniture sanitarie
Quotazione in borsa	14/11/2013
Dipendenti	2.500